BioMarin to Present New Clinical Findings on VOXZOGO at ASBMR Meeting
What happened
BioMarin Pharmaceutical Inc. announced it will present new findings from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting. These studies include results for VOXZOGO (vosoritide) in children with achondroplasia and hypochondroplasia. The presentation will feature new imaging results from a post-hoc analysis evaluating VOXZOGO's effect on the growth of the foramen magnum and craniocervical junction. The company will also share information on the investigational medicine BMN 333.
From prnewswire.com
Why it matters
The presentation provides new insight into the potential effect of VOXZOGO on growth-related dimensions in children with achondroplasia. Positive findings could influence market demand and future investment in treatments for these specific conditions.
From prnewswire.com
Who's involved
- BMDAnnouncing the presentation of clinical study results for VOXZOGO and BMN 333.
- American Society for Bone and Mineral ResearchHosting the annual meeting where BioMarin Pharmaceutical Inc. will present its clinical studies.
Keep exploring
The entities involved
-
American Society for Bone and Mineral Research
medical association
Nothing else this week.